Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to checkpoint inhibitors and...

Epidemic in Pet Cancers Being Fought by Florida Firm, Morphogenesis; Dr. Michael Lawman Discusses ImmuneFx(TM) at World Vaccine Congress TAMPA, Fla., June 26, 2015 (GLOBE NEWSWIRE) -- The incidence of deadly cancers in people worldwide is expected to rise from 13.2 million cases recorded in 2010 to a projected 22.2 million in 2030,...